Abbott Laboratories’ (NYSE:ABT) dorsal root ganglion (DRG) stimulation therapy has advantages over traditional spinal cord stimulation (SCS) in the treatment of patients suffering from complex regional pain syndrome (CRPS). This is according to the latest data that was published in the January edition of Pain. The publication highlighted the real-world insight both in a short-term and long-term approach citing that Abbott’s DRG stimulation therapy continues to support momentum around its adoption. There was also a suggestion of how DRG stimulus benefits patients’ total mood and activity levels.
The condition can negatively impact personal relationships and work productivity.
But such data provide critical hope for treatment options
Jim Broatch, executive vice president and director of RSDSA, an organization that focuses on advancing treatments for patients with CRPS says that the new treatment option can provide significant pain relief for the agonizing pain of CRPS sufferers. The organization has also acknowledged all the physicians and patients who took part in the study because they helped in advancing the understanding of this condition.
On the other hand, lead author of the ACCURATE study publication, Timothy R. Deer wrote, “The findings highlighted in our publication align with what I’ve seen in my practice since U.S. approval of DRG stimulation: that DRG stimulation offers a superior option for CRPS-related chronic pain and improved quality of life for my patients.” Deer is also the CEO of The Center for Pain Relief in Charleston, West Virginia.
Abbott’s Chronic Pain portfolio
Abbott is a universal leader in the development of chronic pain therapy solutions. Apparently, it is also the only medical device manufacturer on the globe that offers radiofrequency ablation (RFA) and spinal cord stimulation (SCS) therapy solutions. It has continued to deliver new products and technologies in various fields the likes of nutrition, diagnostics, medical devices and branded generic pharmaceuticals.
Abbott stock was trading at $40.90 a fall of $0.03 or 0.07%.
